Anika Q2 rev $39.7M (+4%); net loss ($2.8M) vs prior profit $6.5M

Anika Therapeutics, Inc.

2022-Q2 EPS reported -$0.40 revenue$76,350,000

Q2 revenue $39.7M (+4% YoY); OA Pain Mgmt $25.7M (+6%), Joint Preservation $12.1M (+2%).
Net loss ($2.8M) or ($0.20)/share vs prior net income $6.5M ($0.45); adjusted net loss ($1.6M) or ($0.12)/share.
Adjusted EBITDA $4.4M vs $6.1M; cash $91.4M, no debt.
X-Twist Fixation System FDA 510(k) clearance received; limited market release on schedule for 2H 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.